Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry.

about

Paroxysmal nocturnal hemoglobinuria: When delay in diagnosis and long therapy occurs.

P2860

Q54919143-60C56AD2-E417-432D-AC3C-359EB4D211FD

P2860

Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry.

Item

http://www.wikidata.org/entity/Q48287099

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Clinical benefit of eculizumab ...... rnal Haemoglobinuria Registry.

@en

Clinical benefit of eculizumab ...... rnal Haemoglobinuria Registry.

@nl

type

Item

label

Clinical benefit of eculizumab ...... rnal Haemoglobinuria Registry.

@en

Clinical benefit of eculizumab ...... rnal Haemoglobinuria Registry.

@nl

prefLabel

Clinical benefit of eculizumab ...... rnal Haemoglobinuria Registry.

@en

Clinical benefit of eculizumab ...... rnal Haemoglobinuria Registry.

@nl

P1476

Clinical benefit of eculizumab ...... rnal Haemoglobinuria Registry.

@en

P2093

Alexander Cole

http://www.w3.org/2001/XMLSchema#string

Antonio M Almeida

http://www.w3.org/2001/XMLSchema#string

Camille Bedrosian

http://www.w3.org/2001/XMLSchema#string

Hubert Schrezenmeier

http://www.w3.org/2001/XMLSchema#string

Wendell F Rosse

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis and management of paroxysmal nocturnal hemoglobinuria

Thrombosis in paroxysmal nocturnal hemoglobinuria

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials.

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry.

Natural history of paroxysmal nocturnal hemoglobinuria.

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry.

Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.

P304

1026-1034

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IMJ.13523

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jeff Szer

Petra Muus

P577

2017-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28608499

http://www.w3.org/2001/XMLSchema#string

Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry.

about

P2860

P2860

Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698